Foghorn Therapeutics Inc is a biotechnology business based in the US. Foghorn Therapeutics shares (FHTX) are listed on the NASDAQ and all prices are listed in US Dollars. Foghorn Therapeutics employs 95 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Foghorn Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – FHTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Foghorn Therapeutics stock price (NASDAQ: FHTX)Use our graph to track the performance of FHTX stocks over time.
Foghorn Therapeutics shares at a glance
|Latest market close||$10.41|
|52-week range||$9.01 - $28.27|
|50-day moving average||$10.41|
|200-day moving average||$12.93|
|Wall St. target price||$25.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Foghorn Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Foghorn Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Foghorn Therapeutics price performance over time
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-2.25%|
|3 months (2021-04-30)||-5.19%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
Foghorn Therapeutics financials
|Gross profit TTM||$-57,285,000|
|Return on assets TTM||-30.05%|
|Return on equity TTM||-125.81%|
|Market capitalisation||$349.7 million|
TTM: trailing 12 months
Shorting Foghorn Therapeutics shares
There are currently 948,936 Foghorn Therapeutics shares held short by investors – that's known as Foghorn Therapeutics's "short interest". This figure is 1.5% down from 963,607 last month.
There are a few different ways that this level of interest in shorting Foghorn Therapeutics shares can be evaluated.
Foghorn Therapeutics's "short interest ratio" (SIR)
Foghorn Therapeutics's "short interest ratio" (SIR) is the quantity of Foghorn Therapeutics shares currently shorted divided by the average quantity of Foghorn Therapeutics shares traded daily (recently around 208100). Foghorn Therapeutics's SIR currently stands at 4.56. In other words for every 100,000 Foghorn Therapeutics shares traded daily on the market, roughly 4560 shares are currently held short.
To gain some more context, you can compare Foghorn Therapeutics's short interest ratio against those of similar companies.
However Foghorn Therapeutics's short interest can also be evaluated against the total number of Foghorn Therapeutics shares, or, against the total number of tradable Foghorn Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Foghorn Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Foghorn Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0492% of the tradable shares (for every 100,000 tradable Foghorn Therapeutics shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Foghorn Therapeutics.
Find out more about how you can short Foghorn Therapeutics stock.
Foghorn Therapeutics share dividends
We're not expecting Foghorn Therapeutics to pay a dividend over the next 12 months.
Foghorn Therapeutics overview
Foghorn Therapeutics Inc. , a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp.
Stocks similar to Foghorn Therapeutics
Foghorn Therapeutics in the news
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital
Could The Foghorn Therapeutics Inc. (NASDAQ:FHTX) Ownership Structure Tell Us Something Useful?
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Frequently asked questionsWhat percentage of Foghorn Therapeutics is owned by insiders or institutions?
Currently 19.362% of Foghorn Therapeutics shares are held by insiders and 62.904% by institutions. How many people work for Foghorn Therapeutics?
Latest data suggests 95 work at Foghorn Therapeutics. When does the fiscal year end for Foghorn Therapeutics?
Foghorn Therapeutics's fiscal year ends in December. Where is Foghorn Therapeutics based?
Foghorn Therapeutics's address is: 500 Technology Square, Cambridge, MA, United States, 02139 What is Foghorn Therapeutics's ISIN number?
Foghorn Therapeutics's international securities identification number is: US3441741077
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert